Today Caesarstone Sdot-Yam (CSTE) Hits New Lifetime High

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Trade-Ideas LLC identified Caesarstone Sdot-Yam ( CSTE) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified Caesarstone Sdot-Yam as such a stock due to the following factors:

  • CSTE has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $8.9 million.
  • CSTE has traded 2,687 shares today.
  • CSTE is trading at a new lifetime high.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in CSTE with the Ticky from Trade-Ideas. See the FREE profile for CSTE NOW at Trade-Ideas

More details on CSTE:

Caesarstone Sdot-Yam Ltd. and its subsidiaries manufacture and sell engineered quartz surfaces under the Caesarstone brand in the United States, Australia, Canada, Israel, Europe, and internationally.

The average volume for Caesarstone Sdot-Yam has been 275,600 shares per day over the past 30 days. Caesarstone Sdot-Yam has a market cap of $2.1 billion and is part of the industrial goods sector and materials & construction industry. The stock has a beta of 1.61 and a short float of 2.9% with 4.36 days to cover.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Global Stocks Rally as US-China Trade War Thaws; Dow Could Test 25,000

Global Stocks Rally as US-China Trade War Thaws; Dow Could Test 25,000

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)